Loading...

APC anti-human VEGFR-3 (FLT-4) Antibody

Pricing & Availability
Clone
9D9F9 (See other available formats)
Regulatory Status
RUO
Other Names
Receptor tyrosine Kinase VEGFR-3, VEGFR3, FLT4
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
9D9F9_APC_VEGFR3_Antibody_FC_070213
Human endothelial cell line HUVEC was stained with VEGFR3 (clone 9D9F9) APC (filled histogram) or mouse IgG1, κ APC isotype control (open histogram).
  • 9D9F9_APC_VEGFR3_Antibody_FC_070213
    Human endothelial cell line HUVEC was stained with VEGFR3 (clone 9D9F9) APC (filled histogram) or mouse IgG1, κ APC isotype control (open histogram).
Compare all formats See APC spectral data
Cat # Size Price Save
356205 25 tests ¥35,420
356206 100 tests ¥82,280
Description

Receptor tyrosine Kinase VEGFR-3, also known as FLT4, together with VEGFR1 (FIT1) and VEGFR2 (KDR/Flk-1), are the receptors for vascular endothelial growth factors (VEGF). The VEGFR family belongs to the class II subfamily of receptor tyrosine kinases (RTKs), containing a large extracellular region which is composed of seven Ig-like domains (D1–D7), a single transmembrane, helix, and a cytoplasmic region with tyrosine kinase activity. In VEGFR-3, the fifth Ig homology domain is proteolytically cleaved which results in polypeptides that remain linked by two disulfide bonds. VEGFR-3 is widely expressed on all endothelial cells in early embryogenesis, while, in adult tissues, VEGFR-3 expression disappears from the vascular endothelial cells and is observed only on the lymphatic endothelium. VEGF-C and VEGF-D activation of VEGFR-3 plays an important role in the formation of the lymphatic vessel system. Aberrant activation or expression of VEGFR and their ligands has been implicated in tumor angiogenesis, coronary artery disease, diabetic blindness, and other diseases.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Human
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
VEGFR extracellular domain protein
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography and conjugated with APC under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Red Laser (633 nm)
Application Notes

Additional reported applications (for relevant formats) include: immunohistochemistry staining of frozen or paraffin embedded sections1-3.

Application References

(PubMed link indicates BioLegend citation)
  1. Jussila L, et al. 1998. Cancer Res. 58:1599. (IHC)
  2. Kilic N, et al. 2007. Blood 110:4223. (IHC)
  3. Folpe A, et al. 2000. Mod. Pathol. 13:180. (IHC)
RRID
AB_2562276 (BioLegend Cat. No. 356205)
AB_2562276 (BioLegend Cat. No. 356206)

Antigen Details

Structure
Seven Ig-like domains in the extracellular domain, a single transmembrane helix, and a cytoplasmic region with tyrosine kinase activity
Distribution

Widely expressed in early embryogenesis endothelial cells, restrictly expressed on lymphatic endothelial cells in adults

Function
Mediates lymphangiogenesis in response to VEGF-C and VEGF-D, involved in cardiovascular development during embryogenesis
Ligand/Receptor
VEGF-C, VEGF-D
Biology Area
Cell Biology, Immunology, Signal Transduction
Molecular Family
Cytokine/Chemokine Receptors
Antigen References

1. Tammela T, et al. 2008. Nature 454:656.
2. Partanen TA, et al. 2000. FASEB J. 14:2087.
3. Valtola R, et al. 1999. Am. J. Pathol. 154:1381.
4. Jussila L, et al. 1998. Cancer Res. 58:1599.
5. Galland F, et al. 1992. Genomics 13:475.

Gene ID
2324 View all products for this Gene ID
UniProt
View information about VEGFR-3 on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 2    Revision Date: 09/22/2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account